Centerline Biomedical
A Cleveland clinic spin-off, is developing an innovative system.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $33.0m | Series B | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 167 % | 77 % | 15 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Centerline Biomedical, a spin-off from the Cleveland Clinic, specializes in advanced surgical navigation technology. The company's flagship product, the Intra Operative Positioning System (IOPS), is a 3D GPS-like system designed to enhance surgical precision, simplify complex procedures, and reduce radiation exposure for both patients and healthcare professionals. Operating primarily in the healthcare sector, Centerline Biomedical serves hospitals, surgical centers, and medical professionals who perform endovascular procedures. The business model revolves around the sale and licensing of its proprietary technology, along with providing ongoing support and training services. Revenue is generated through direct sales, licensing agreements, and service contracts. Centerline Biomedical's market includes healthcare institutions looking to improve surgical outcomes and patient safety through cutting-edge technology.
Keywords: 3D navigation, surgical precision, endovascular, healthcare technology, radiation reduction, Cleveland Clinic, IOPS, medical innovation, surgical support, patient safety.